explore -WSS

explore

author：hotspot 2025-10-01 12:11:41 - browse：966

Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And will there ever be an Apple of pharma?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

For more on what we cover, here’s the news on the Wegovy study; here’s more on its implications; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Novo: Oral version of Ozempic leads to 15% weight loss

entertainment

WSS

Doctors on social media are being harassed and cyberbullied

Timeline: Key moments in fight for gay rights

Timeline: Key moments in fight for gay rights

Xenotransplantation trials will require adjusting expectations, experts say

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Mom launches Girl Scout troop for LGBTQ youth in Texas

hotspot

explore

explore

How one medical school became remarkably diverse

How to fix the rural physician shortage in the U.S.

Medical leaders decry Supreme Court decision on affirmative action

Millions may soon lose Medicaid when they don't have to

How to save PrEP access — and even expand it

Senate panel passes drug pricing bills, but drops one PBM reform

Apple is now the first public company to be valued at $3 trillion

AMAs digital advisors table RPM coding reform proposal, again

Duchenne breakthrough therapy leaves behind pioneering families

Eli Lilly reports tirzepatide MASH success during Q4 earnings

entertainment

Congress considering partial increase for doctor pay in Medicare

How to fix the rural physician shortage in the U.S.

Bernie Sanders gets little from pharma CEOs on drug prices

Bispecific antibodies are next new thing in cancer immunotherapy

Reanimated hearts work just as well for transplants, study finds

Bispecific antibodies are next new thing in cancer immunotherapy

hotspot

entertainment

explore

hotspot